Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Despite FDA REMS Program, Large Number Of Patients Prescribed Fentanyl, Study Finds February 21, 2019 Martha Garcia Add Your Comments More than half of patients prescribed the powerful and fast-acting painkiller fentanyl do not need the medication, and do not meet the federal requirements put in place to restrict use due to the potentially fatal side effects, according to the findings of a new study. Researchers from Johns Hopkins published a study in the Journal of the American Medical Association (JAMA) on February 19, indicating that many doctors are still prescribing transmucosal immediate-release fentanyl (TIRF) off-label for patients who do not have cancer pain or other types of severe pain. The data raises questions about the effectiveness of the U.S. Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategy (REMS) for the transmucosal immediate-release fentanyl. The program was designed to help prevent inappropriate use of fast-acting fentanyl products, like prescribing them to patients without a tolerance to opioid painkillers. It’s designed to help reduce the risk of side effects, including misuse and abuse. Learn More About Fentanyl Patch Lawsuits Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Fentanyl Patch Lawsuits Learn More SEE IF YOU QUALIFY FOR COMPENSATION Fentanyl is an opioid that is 50 to 100 times more powerful than morphine and the cause of more than half of drug overdoses. It is delivered through lozenges, sprays, and tablets. It goes into the bloodstream in seconds. Fast-acting fentanyl is approved by the FDA to be used for severe cancer pain that isn’t effectively reduced with round-the-clock opioids. It is also approved to treat patients who are tolerant to opioids, but still experience severe pain. Fast-acting fentanyl products are potent and fast acting but have a higher risk of fatal overdose for patients who don’t need them, like those that are not tolerant to the effects of traditional opioids. Last year, the CDC issued a warning about fentanyl, and it is now considered the most dangerous drug in America. Researchers reviewed FDA documents from 2012 to 2017, including nearly 5,000 pages of data from six annual REMS reports. The reports included surveys of patients, doctors, and pharmacists. Surveys completed 12 months after the program began indicate that 86% of pharmacists, 87% of doctors, and 91% of patients knew the fentanyl products are not recommended for patients who do not have opioid tolerance or severe untreatable cancer pain. However, after a four-year period, 51% of patients who did not have an opioid tolerance were prescribed fentanyl by their doctor. Roughly 34% of doctors continued to prescribe the fentanyl products to patients who didn’t need the drugs, or non-tolerant patients, at the four year mark. By five years, anywhere from 35% to 55% of patients who received the fentanyl products did not need them. Similarly, at the five-year mark, 18% of doctors and nearly 50% of patients inaccurately said it was okay to take fentanyl for non-cancer or non-severe pain. Despite the purpose of the program, many doctors and patients are still receiving incorrect information that can put them at risk for abuse or overdose, the researchers determined. Lack Of Oversight Not only was there inappropriate prescribing to patients who don’t need the fentanyl products, but there was a lack of oversight by the agency regarding the potent products and its use for patients, the researchers warned. The data indicates fast-acting fentanyl products were prescribed off-label in many cases. While doctors are usually allowed to prescribe drugs for any purpose they see fit, drugs that are part of a REMS program are different. Doctors must be enrolled and their access to that drug is dependent upon close adherence of the rules of the REM program, which does not allow off-label prescribing. Despite the widespread misuse and inappropriate prescribing, the FDA did not disenroll doctors who did this from the REMS program. In fact, much of the time it is prescribed for many different conditions other than cancer pain, such as arthritis, which is not an approved use. Tags: Drug Abuse, Drug Overdose, Fentanyl, Fentanyl Overdose, Opioid Image Credit: | More Fentanyl Patch Lawsuit Stories U.S. Drug Overdose Deaths Increased 30% to All-Time High in 2020: CDC July 20, 2021 Synthetic Opioid Deaths Increased More Than 1,000% In Recent Years: CDC February 12, 2021 FDA Announces New Risk Mitigation Strategy To Address Opioid Crisis December 28, 2020 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermEmailThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Lawsuit Claims Paul Mitchell, Redken, Other Hair Dyes Led to Bladder Cancer Diagnosis for Hairdresser (Posted: 2 days ago) A hairdresser who has worked for nearly 40 years in the industry says her constant exposure to hair dye led to a bladder cancer diagnosis. MORE ABOUT: HAIR DYE LAWSUITSalon Stylist Files Lawsuit Over Bladder Cancer From Hair Dye Products (05/02/2025)Hair Color Lawsuit Alleges Bladder Cancer Caused by Salon Dye (04/25/2025)Hair Dye Cancer Lawsuit Filed Over Wrongful Death of Salon Professional (04/11/2025) First Oxbryta Lawsuit Set for Trial in August 2027, Over Recalled Sickle Cell Drug Risks (Posted: 2 days ago) An Oxbryta class action lawsuit has been scheduled for trial in August 2027, but must first survive a motion to dismiss filed by manufacturers. MORE ABOUT: OXBRYTA LAWSUITMalpractice Lawsuit Alleges Side Effects of Oxbryta Caused Untimely Death (04/15/2025)At Least 8 Lawsuits Over Oxbryta Filed Against Pfizer, Global Blood Therapeutics (03/14/2025)After Recalling Oxbryta, Pfizer Seeks Dismissal of Class Action Brought by Former Users (03/07/2025) Court Urged To Combine 5 AFFF Lawsuits For First MDL Bellwether Trial (Posted: 3 days ago) Plaintiffs have asked the judge presiding over all AFFF lawsuits to consolidate five claims involving kidney cancer and testicular cancer injuries for the first bellwether trial in the federal MDL. MORE ABOUT: AFFF LAWSUITAdditional AFFF Ulcerative Colitis Lawsuits Added to Bellwether Discovery Pool (04/29/2025)Firefighter Unions File Class Action Lawsuit Over Cancer-Causing Chemicals in Protective Gear (04/25/2025)Pennsylvania Residents File Class Action Lawsuit Over Jet Fuel Pipeline Leak (03/31/2025)
Lawsuit Claims Paul Mitchell, Redken, Other Hair Dyes Led to Bladder Cancer Diagnosis for Hairdresser (Posted: 2 days ago) A hairdresser who has worked for nearly 40 years in the industry says her constant exposure to hair dye led to a bladder cancer diagnosis. MORE ABOUT: HAIR DYE LAWSUITSalon Stylist Files Lawsuit Over Bladder Cancer From Hair Dye Products (05/02/2025)Hair Color Lawsuit Alleges Bladder Cancer Caused by Salon Dye (04/25/2025)Hair Dye Cancer Lawsuit Filed Over Wrongful Death of Salon Professional (04/11/2025)
First Oxbryta Lawsuit Set for Trial in August 2027, Over Recalled Sickle Cell Drug Risks (Posted: 2 days ago) An Oxbryta class action lawsuit has been scheduled for trial in August 2027, but must first survive a motion to dismiss filed by manufacturers. MORE ABOUT: OXBRYTA LAWSUITMalpractice Lawsuit Alleges Side Effects of Oxbryta Caused Untimely Death (04/15/2025)At Least 8 Lawsuits Over Oxbryta Filed Against Pfizer, Global Blood Therapeutics (03/14/2025)After Recalling Oxbryta, Pfizer Seeks Dismissal of Class Action Brought by Former Users (03/07/2025)
Court Urged To Combine 5 AFFF Lawsuits For First MDL Bellwether Trial (Posted: 3 days ago) Plaintiffs have asked the judge presiding over all AFFF lawsuits to consolidate five claims involving kidney cancer and testicular cancer injuries for the first bellwether trial in the federal MDL. MORE ABOUT: AFFF LAWSUITAdditional AFFF Ulcerative Colitis Lawsuits Added to Bellwether Discovery Pool (04/29/2025)Firefighter Unions File Class Action Lawsuit Over Cancer-Causing Chemicals in Protective Gear (04/25/2025)Pennsylvania Residents File Class Action Lawsuit Over Jet Fuel Pipeline Leak (03/31/2025)